Eculizumab (Soliris) has undergone assessment for the indication of atypical haemolytic uremic syndrome via a Europe-wide centralised variation procedure. The Committee for Medicinal Products for Human Use, as well as the Commission on Human Medicines (UK) considered, and have recommended the granting of the extension of indication. Eculizumab is now licensed for the indication.